The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The current landscape of treatment for HR-MDS: an update from ASH 2023
Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the current landscape of treatment for higher-risk myelodysplastic syndromes (HR-MDS). Although transplantation is the gold standard, eligibility is limited for most patients. Ongoing clinical trials explore combinations of hypomethylating agents (HMAs), immunotherapies, small molecule inhibitors, and targeted therapies with the aim of enhancing survival outcomes and delaying progression to acute myeloid leukemia (AML). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
